Technology and expertise
to fit your needs
Emerging and Mid-Sized Biopharma companies rely on Medidata to gain speed, scale as complexity increases, mitigate risks, and improve trial outcomes.
Medicenna: Solving the Impossible in Glioblastoma with Medidata Acorn AI Synthetic Control Arm® (SCA®)
Hear how Medicenna Therapeutics, Inc worked with the Acorn AI team to become the first to get an FDA agreement to design a phase 3 registrational trial using an external control arm.
Proven innovative technology fit to your needs
Transformative technology for early-stage research now, that scales as study design complexity increases tomorrow. Battle tested on over 3K Phase I Studies and 2.6K+ Single Site Studies.
Mitigate risk with the ecosystem trusted by life science partners
Medidata puts your trials at the center of the life science ecosystem. Our relationships span across academic, regulatory, patient advocacy and scientific organizations of all sizes. Trusted by 900k+ site/sponsors and over 150 global CROs and partners.
Move faster with dedicated support and expertise
Leverage best practices from 24,000+ trials and 1,200 relationships with emerging and mid-size biopharma companies to improve your trial outcomes.
Right-size your team, access data to make better decisions, pivot faster, generate “evidence” needed, and position for regulatory success.
One technology platform to power people, processes, and progress.
Medidata helps Emerging and Mid-Sized Biopharma companies adapt, simplify, scale, and accelerate their clinical trials, from protocol design to study startup, conduct, close-out, and commercialization. Our platform is built to enable you with cloud-based, modular, integrable, easily configurable capabilities, all powered by the latest patient, clinical and operational data, and AI solutions.
The industry’s only complete decentralized clinical trial solution
There’s no doubt about it. The decentralized trial is here to stay. That leaves leaders of emerging and mid-sized biopharma with one question: Who can help you start running easy-to-implement and cost-effective virtual, hybrid, and decentralized trials right now?
Truth in data:
- 800+ studies
- 600K+ patients
- 44K+ sites using a Medidata DCT solution
Read more about our end-to-end decentralized clinical trial solutions for emerging and mid-sized biopharma.
The industry’s only platform to leverage cross-industry clinical trial data
You need faster insights for faster action. Not disparate data from disparate sources. Elevate your organization and future-proof your trials with connected, standardized data – for clearer visibility across trials and more actionable insights.
Truth in data:
- Clinical trial data from 7 million patients and 25,000+ trials
- 45B+ data points
- 63% growth in data volume in 4 years
Learn more about our data and analytics solutions for emerging and mid-sized biopharma.
The results-driven approach to unifying teams, data, and processes
Do more with less by unifying your teams, data, applications, and processes in one easily accessible place. With a seamless and intuitive cloud-based platform, you can enhance visibility across trials, increase operational efficiencies, and decrease trial timelines.
Truth in data:
- 5 days to reach database lock
- 80% reduction in data correction rates
- 40% reduction in edit checks
Learn more about our unified technology platform for emerging and mid-sized biopharma.
The industry’s most comprehensive patient-centric solutions
Regardless of the size of your organization, patients are at the heart of everything you do. From patient enrollment to retention, we help emerging and mid-sized biopharma engage more patients -more effectively- with trial decentralization and patient-first tech at every step.
Truth in data:
- Cross-industry clinical trial data from over 25,000 trials and over 7 million patients
- Datasets pre-integrated with real world data
Learn more about our patient-centric clinical trial solutions for emerging and mid-sized biopharma.
Resources for Mid-Sized Biopharma
Decentralized Clinical Trial Technology
Disruptions preventing or limiting site access to patients, monitors, and CRAs are propelling long-lasting changes.
Are you set to adopt a decentralized clinical trial strategy?
Hear how executives at TissueTech, Rezolute, and UroGen Pharma have achieved greater pace and performance results.
The Data to Increase Success
Data is at the core of study success.
Optimize trial design, accelerate patient enrollment, improve operations, and proactively improve data quality.